Chondroitin and glucosamine in the management of osteoarthritis: An update topical collection on complementary and alternative medicine

Current Rheumatology Reports

Volumn 15, Issue 10, 2013, Pages

  Henrotin, Yves ^a   Lambert, Cécile ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Animal studies; Cartilage; Chondroitin sulfate; Clinical efficacy; Complementary and alternative medicine; Glucosamine; Osteoarthritis; Treatment

Indexed keywords

CHONDROITIN; GLUCOSAMINE;

DIET SUPPLEMENTATION; HUMAN; OSTEOARTHRITIS; TREATMENT OUTCOME;

CHONDROITIN; DIETARY SUPPLEMENTS; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 84896421136     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0361-z     Document Type: Article

References (97)

1. Aghazadeh-Habashi A, Jamali F. The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci. 2011;14(2):264-73.
2. Ali AA, Lewis SM, Badgley HL, et al. Oral glucosamine increases expression of transforming growth factor beta1 (TGFbeta1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: implications for human efficacy and toxicity. Arch Biochem Biophys. 2011;510(1):11-8. doi: 10.1016/j.abb.2011.03.014.
3. Baccarin RYA, Machado TSL, Lopes-Moraes AP, et al. Urinary glycosaminoglycans in horse osteoarthritis. Effects of chondroitin sulfate and glucosamine. Res Vet Sci. 2012;93(1):88-96. doi: 10.1016/j.rvsc.2011.08.009.
4. Bassleer CT, Combal JP, Bougaret S, Malaise M. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthr Cartil. 1998;6(3):196-204. doi: 10.1053/joca.1998.0112. (Pubitemid 28255110)
5. Bauerova K, Ponist S, Kuncirova V, et al. Chondroitin sulfate effect on induced arthritis in rats. Osteoarthr Cartil. 2011;19(11):1373-9. doi: 10.1016/j.joca.2011.08.006.
6. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65(2):222-6. doi: 10.1136/ard.2005.036368. (Pubitemid 43131997)
7. Block JA, Oegema TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthr Cartil. 2010;18(1):5-11. doi: 10.1016/j.joca.2009.07.005.
8. Bruyere O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord. 2008;9:165. doi: 10.1186/1471-2474-9-165.
9. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil. 2008;16(2):254-60. doi: 10.1016/j.joca.2007.06.011. (Pubitemid 351218188)
10. • Calamia V, Fernández-Puente P, Mateos J et al. Pharmacoproteomic Study of Three Different Chondroitin Sulfate Compounds on Intracellular and Extracellular Human Chondrocyte Proteomes. Molecular & Cellular Proteomics. 2012;11(6). doi: 10.1074/mcp.M111.013417. Relevant confirmation of the different effects of different CS formulations using state-of-the-art technology
11. •• Calamia V, Lourido L, Fernandez-Puente P, et al. Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther. 2012;14(5):R202. doi: 10.1186/ar4040. Up-to-date report of the different effects of CS.
12. •• Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4):R138. doi: 10.1186/ar3077. Interesting approach with the latest technology providing additional data about mechanism of action of both GlcN and CS.
13. Campo GM, Avenoso A, Campo S, et al. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther. 2003;5(3):R122-31.
14. Campo GM, Avenoso A, Campo S, et al. Antioxidant activity of chondroitin sulfate. Adv Pharmacol. 2006;53:417-31. doi: 10.1016/S1054-3589(05)53020-5.
15. Campo GM, Avenoso A, Campo S, et al. Chondroitin sulphate: antioxidant properties and beneficial effects. Mini Rev Med Chem. 2006;6(12):1311-20. (Pubitemid 44890538)
16. Campo GM, Avenoso A, Campo S, et al. Chondroitin-4-sulphate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice. Osteoarthr Cartil. 2008;16(12):1474-83. doi: 10.1016/j.joca.2008.04.002.
17. Campo GM, Avenoso A, Campo S, et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem. 2009;106(1):83-92. doi: 10.1002/jcb.21981.
18. Campo GM, Avenoso A, Campo S, et al. Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. Arch Biochem Biophys. 2009;491(1-2):7-15. doi: 10.1016/j.abb.2009.09.017.
19. Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res. 2005;66(11):1870-6. (Pubitemid 43091705)
20. Chan PS, Caron JP, Orth MW. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res. 2007;68(7):709-15. doi: 10.2460/ajvr.68.7.709. (Pubitemid 47162467)
21. • Chiusaroli R, Piepoli T, Zanelli T et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011;2011:939265. doi: 10.1155/2011/939265. Relevant results obtained with low doses of GlcN
22. Cho SY, Sim JS, Jeong CS, et al. Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice. Biol Pharm Bull. 2004;27(1):47-51. (Pubitemid 41656671)
23. Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood). 2005;230(4):255-62. (Pubitemid 40478250)
24. Clegg D, Reda D, Harris C, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808. (Pubitemid 43290918)
25. David-Raoudi M, Deschrevel B, Leclercq S, et al. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt. Arthritis Rheum. 2009;60(3):760-70. doi: 10.1002/art.24302.
26. du Souich P, Garcia AG, Verges J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;13(8A):1451-63. doi: 10.1111/j.1582-4934.2009.00826.x.
27. •• Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63(11):3383-91. doi: 10.1002/art.30574. One of the latest clinical trials of CS, documenting the effect of using a highly purified formulation.
28. Gupta RC, Canerdy TD, Skaggs P, et al. Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses. J Vet Pharmacol Ther. 2009;32(6):577-84. doi: 10.1111/j.1365-2885.2009.01079.x.
29. Henrotin YE. Interpretation of metaanalyses: pitfalls should be more widely recognized. J Rheumatol. 2012;39(6):1107-9. doi: 10.3899/jrheum.111420.
30. Henrotin Y, Chevalier X, Herrero-Beaumont G, et al. Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Res Notes. 2013;6:115. doi: 10.1186/1756-0500-6-115.
31. Henrotin Y, Mathy M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis. 2010;2(6):335-48. doi: 10.1177/1759720X10383076.
32. • Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012;14(1):201. doi: 10.1186/ar3657. Interesting and comprehensive points of view about the different aspects of GlcN in OA.
33. Hochberg M. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil. 2010;18 Suppl 1:S28-31.
34. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-74.
35. Hochberg M, Chevalier X, Henrotin Y, et al. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin. 2013;29(3):259-67. doi: 10.1185/03007995.2012.753430.
36. Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin. 2008. doi: 10.1185/03007990802434932.
37. Holzmann J, Brandl N, Zemann A, et al. Assorted effects of TGFbeta and chondroitinsulfate on p38 and ERK1/2 activation levels in human articular chondrocytes stimulated with LPS. Osteoarthr Cartil. 2006;14(6):519-25. (Pubitemid 43785848)
38. Hong H, Park YK, Choi MS, et al. Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride. J Dermatol Sci. 2009;56(1):43-50. doi: 10.1016/j.jdermsci.2009.06.017.
39. Hua J, Suguro S, Hirano S, et al. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res. 2005;54(3):127-32. doi: 10.1007/s00011-004-1333-6. (Pubitemid 40767560)
40. Igarashi M, Kaga I, Takamori Y, et al. Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med. 2011;27(6):821-7. doi: 10.3892/ijmm.2011.662.
41. Igarashi M, Sakamoto K, Nagaoka I. Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation. Int J Mol Med. 2011;28(3):373-9. doi: 10.3892/ijmm.2011.686.
42. Imada K, Oka H, Kawasaki D, et al. Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull. 2010;33(3):410-4.
43. Imagawa K, de Andres MC, Hashimoto K, et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes-implications for osteoarthritis. Biochem Biophys Res Commun. 2011;405(3):362-7. doi: 10.1016/j.bbrc.2011.01.007.
44. Ivanovska N, Dimitrova P. Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther. 2011;13(2):R44. doi: 10.1186/ar3283.
45. • Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthr Cartil. 2010;18(3):297-302. doi: 10.1016/j.joca.2009.10. 013. Important information regarding the pharmacokinetics of both compounds.
46. Jomphe C, Gabriac M, Hale TM, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008;102(1):59-65. doi: 10.1111/j.1742-7843.2007.00158.x. (Pubitemid 350301907)
47. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. (Pubitemid 37500619)
48. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524-33.
49. Kapoor M, Mineau F, Fahmi H, et al. Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012;39(3):635-44. doi: 10.3899/jrheum.110621.
50. Katta J, Jin Z, Ingham E, Fisher J. Chondroitin sulphate: an effective joint lubricant? Osteoarthr Cartil. 2009;17(8):1001-8. doi: 10.1016/j.joca.2009. 02.010.
51. Kim MM, Mendis E, Rajapakse N, Kim S-K. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett. 2007;17(7):1938-42. doi: 10.1016/j.bmcl.2007.01.030. (Pubitemid 46367668)
52. Kobayashi T, Notoya K, Nakamura A, Akimoto K. Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005;54(6):249-55. doi: 10.1007/s00011-005-1351-z. (Pubitemid 40853840)
53. Lambert C, Mathy-Hartert M, Dubuc JE, et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther. 2012;14(2):R58. doi: 10.1186/ar3771.
54. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil. 2003;11(4):290-8. (Pubitemid 36410882)
55. • Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010;30(3):357-63. doi: 10.1007/s00296-009-0969-5. One of the latest meta-analyses.
56. Legendre F, Bauge C, Roche R, et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes - study in hypoxic alginate bead cultures. Osteoarthr Cartil. 2008;16(1):105-14. doi: 10.1016/j.joca.2007.05.020.
57. Lin YC, Liang YC, Sheu MT, et al. Chondroprotective effects of glucosamine involving the p38 MAPK and Akt signaling pathways. Rheumatol Int. 2008;28(10):1009-16. doi: 10.1007/s00296-008-0561-4.
58. • Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-707. doi: 10.1002/art.34453. Latest statement of OA as a disease involving all the tissues of the joint.
59. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283(11):1469-75. (Pubitemid 30151826)
60. Mendis E, Kim M-M, Rajapakse N, Kim S-K. Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-[kappa]B and MAPK expressions. Bioorg Med Chem. 2008;16(18):8390-6. doi: 10.1016/j.bmc.2008.08. 037.
61. Mendis E, Kim MM, Rajapakse N, Kim SK. The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. Bioorg Med Chem Lett. 2009;19(10):2755-9. doi: 10.1016/j.bmcl.2009.03.126.
62. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52(3):779-86. doi: 10.1002/art.20867. (Pubitemid 40365099)
63. Monfort J, Nacher M, Montell E, et al. Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res. 2005;31(2):71-6. (Pubitemid 350056458)
64. Naito K, Watari T, Furuhata A, et al. Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model. Life Sci. 2010;86(13-14):538-43. doi: 10.1016/j.lfs.2010.02.015.
65. Nakamura H, Shibakawa A, Tanaka M, et al. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 2004;22(3):293-9. (Pubitemid 38585231)
66. Oegema Jr TR, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum. 2002;46(9):2495-503. doi: 10.1002/art.10499.
67. Omata T, Itokazu Y, Inoue N, Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung. 2000;50(2):148-53. doi: 10.1055/s-0031-1300180. (Pubitemid 30114844)
68. Oryan A, Moshiri A, Meimandiparizi A-H. Effects of sodium-hyaluronate and glucosamine-chondroitin sulfate on remodeling stage of tenotomized superficial digital flexor tendon in rabbits: a clinical, histopathological, ultrastructural, and biomechanical study. Connect Tissue Res. 2011;52(4):329-39. doi: 10.3109/03008207.2010.531332.
69. • Pecchi E, Priam S, Mladenovic Z, et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts. Osteoarthr Cartil. 2012;20(2):127-35. doi: 10.1016/j.joca.2011.12. 002. Recent data regarding the effect of CS on subchondral bone.
70. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother. 2005;39(6):1080-7. doi: 10.1345/aph.1E576. (Pubitemid 40695976)
71. Rafi MM, Yadav PN, Rossi AO. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. Mol Nutr Food Res. 2007;51(5):587-93. (Pubitemid 47083696)
72. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268-77. (Pubitemid 351665485)
73. Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008;66(3):244-50.
74. Tahiri K, Korwin-Zmijowska C, Richette P, et al. Natural chondroitin sulphates increase aggregation of proteoglycan complexes and decrease ADAMTS-5 expression in interleukin 1 beta-treated chondrocytes. Ann Rheum Dis. 2008;67(5):696-702. doi: 10.1136/ard.2007.078600. (Pubitemid 351571936)
75. Taniguchi S, Ryu J, Seki M, et al. Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. J Orthop Res. 2012;30(5):673-8. doi: 10.1002/jor.22003.
76. Tat SK, Pelletier JP, Mineau F, et al. Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process. J Rheumatol. 2010;37(3):656-64. doi: 10.3899/jrheum.090696.
77. Tat SK, Pelletier JP, Vergés J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts. Arthritis Res Ther. 2007;9:R117.
78. Tiraloche G, Girard C, Chouinard L, et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 2005;52(4):1118-28. doi: 10.1002/art.20951. (Pubitemid 40530119)
79. Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2006(3):(online).
80. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil. 2004;12(4):269-76. doi: 10.1016/j.joca.2004.01.004. (Pubitemid 38461289)
81. Vallieres M, du Souich P. Modulation of inflammation by chondroitin sulfate. Osteoarthr Cartil. 2010;18 Suppl 1:S1-6. doi: 10.1016/j.joca.2010.02. 017.
82. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56(7):2267-77. doi: 10.1002/art.22728. (Pubitemid 47173575)
83. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007;96(12):3168-80. doi: 10.1002/jps.20997.
84. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009;61(10):1271-80. doi: 10.1211/jpp/61.10.0002.
85. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology. 2011;19(6):299-306. doi: 10.1007/s10787-011-0098-0.
86. Wandel S, Juni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
87. Wang SX, Laverty S, Dumitriu M, et al. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum. 2007;56(5):1537-48. doi: 10.1002/art.22574. (Pubitemid 46764083)
88. Wang L, Wang J, Almqvist KF, et al. Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Clin Exp Rheumatol. 2002;20(5):669-76. (Pubitemid 35243780)
89. Wen ZH, Tang CC, Chang YC, et al. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthr Cartil. 2010;18(9):1192-202. doi: 10.1016/j.joca.2010.05.012.
90. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis - an untreatable disease? Nat Rev Drug Discov. 2005;4(4):331-44. doi: 10.1038/nrd1693. (Pubitemid 41130946)
91. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70(6):982-9. doi: 10.1136/ard.2010.140848.
92. Zegels B, Crozes P, Uebelhart D, et al. Equivalence of a single dose (1200 mg) compared with a three-time a day dose (400 mg) of chondroitin 4 and 6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21(1):22-7. doi: 10.1016/j.joca.2012.09.017.
93. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669-81. doi: 10.1136/ard.2004.028886. (Pubitemid 40559291)
94. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377-88. doi: 10.1136/ard.2006.062091. (Pubitemid 46579641)
95. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil. 2007;15(9):981-1000. (Pubitemid 47393443)
96. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137-62. (Pubitemid 351222155)
97. •• Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18(4):476-99. doi: 10.1016/j.joca.2010.01.013. Update of effect size (ES) for both compounds, and comprehensive analysis.